OBJECTIVE: The Functional Living Index-Emesis (FLIE) instrument is a validated nausea and vomiting specific quality of life (QOL) tool originally created as a 3-day test of the impact of chemotherapy-induced nausea and vomiting on cancer patients' daily life. The primary objective of the present study was to retrospectively explore the use of the FLIE from data obtained in a previously published study of patients with gastrointestinal radiation-induced nausea and vomiting (RINV) and compare the extracted symptom clusters on a weekly basis for the entirety of gastrointestinal cancer patients' radiotherapy treatments. METHODS: QOL was assessed on a weekly basis using the 18-item FLIE questionnaire for patients' radiotherapy treatments. A principal component analysis with varimax rotation was performed at each visit. The internal consistency and reliability of the derived clusters was assessed with Cronbach's alpha. Robust relationship and correlation among symptoms was displayed with biplot graphics. RESULTS: A total of 460 FLIE assessments were completed for the 86 gastrointestinal patients who underwent radiotherapy. Two components were consistently identified except for week 5 where only one component was identified. Component 1 contained the items "Q10-Q18" which included all vomiting items. Component 2 included all nausea items from "Q1 to Q9". All the variables were well accounted for by two components for most weeks of treatment with excellent internal consistency. Biplots indicate that the two symptom clusters were evident at each week, with the exception of the first week of treatment. Strong correlations were seen between the effect of nausea on patients' ability to make meals, patients' ability to do tasks within the home, and patients' willingness to spend time with family and friends. CONCLUSION: The high internal consistency at all timepoints indicates that the FLIE QOL instrument is useful for the RINV population.
OBJECTIVE: The Functional Living Index-Emesis (FLIE) instrument is a validated nausea and vomiting specific quality of life (QOL) tool originally created as a 3-day test of the impact of chemotherapy-induced nausea and vomiting on cancerpatients' daily life. The primary objective of the present study was to retrospectively explore the use of the FLIE from data obtained in a previously published study of patients with gastrointestinal radiation-induced nausea and vomiting (RINV) and compare the extracted symptom clusters on a weekly basis for the entirety of gastrointestinal cancerpatients' radiotherapy treatments. METHODS: QOL was assessed on a weekly basis using the 18-item FLIE questionnaire for patients' radiotherapy treatments. A principal component analysis with varimax rotation was performed at each visit. The internal consistency and reliability of the derived clusters was assessed with Cronbach's alpha. Robust relationship and correlation among symptoms was displayed with biplot graphics. RESULTS: A total of 460 FLIE assessments were completed for the 86 gastrointestinalpatients who underwent radiotherapy. Two components were consistently identified except for week 5 where only one component was identified. Component 1 contained the items "Q10-Q18" which included all vomiting items. Component 2 included all nausea items from "Q1 to Q9". All the variables were well accounted for by two components for most weeks of treatment with excellent internal consistency. Biplots indicate that the two symptom clusters were evident at each week, with the exception of the first week of treatment. Strong correlations were seen between the effect of nausea on patients' ability to make meals, patients' ability to do tasks within the home, and patients' willingness to spend time with family and friends. CONCLUSION: The high internal consistency at all timepoints indicates that the FLIE QOL instrument is useful for the RINV population.
Authors: Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman Journal: J Clin Oncol Date: 2011-09-26 Impact factor: 44.544
Authors: Michael Poon; Kristopher Dennis; Carlo DeAngelis; Hans Chung; Jordan Stinson; Liying Zhang; Gillian Bedard; Marko Popovic; Nicholas Lao; Natalie Pulenzas; Shun Wong; Edward Chow Journal: Support Care Cancer Date: 2014-01-12 Impact factor: 3.603
Authors: P A Farley; C L Dempsey; A A Shillington; C Kulis-Robitaille; K Colgan; G Bernstein Journal: Am J Health Syst Pharm Date: 1997-11-01 Impact factor: 2.637
Authors: Rebecca K S Wong; Nancy Paul; Keyue Ding; Marlo Whitehead; Michael Brundage; Anthony Fyles; Derek Wilke; Abdenour Nabid; Andre Fortin; Don Wilson; Michael McKenzie; Ida Ackerman; Luis Souhami; Pierre Chabot; Joseph Pater Journal: J Clin Oncol Date: 2006-07-20 Impact factor: 44.544
Authors: Ernesto Maranzano; Verena De Angelis; Stefano Pergolizzi; Marco Lupattelli; Paolo Frata; Stefano Spagnesi; Maria Luisa Frisio; Giovanni Mandoliti; Giuseppe Malinverni; Fabio Trippa; Letizia Fabbietti; Salvatore Parisi; Annamaria Di Palma; Pietro De Vecchi; Costantino De Renzis; Celestino Giorgetti; Tiziano Bergami; Roberto Orecchia; Maurizio Portaluri; Marco Signor; Davide Di Gennaro Journal: Radiother Oncol Date: 2009-12-04 Impact factor: 6.280
Authors: Arash Naeim; Sydney M Dy; Karl A Lorenz; Homayoon Sanati; Anne Walling; Steven M Asch Journal: J Clin Oncol Date: 2008-08-10 Impact factor: 44.544
Authors: Anna Enblom; Beata Bergius Axelsson; Gunnar Steineck; Mats Hammar; Sussanne Börjeson Journal: Support Care Cancer Date: 2008-06-05 Impact factor: 3.603
Authors: A R Martin; A D Carides; J D Pearson; K Horgan; M Elmer; C Schmidt; B Cai; S P Chawla; S M Grunberg Journal: Eur J Cancer Date: 2003-07 Impact factor: 9.162
Authors: Caitlin Yee; Leah Drost; Liying Zhang; Bo Angela Wan; Vithusha Ganesh; May Tsao; Elizabeth Barnes; Mark Pasetka; Carlo DeAngelis; Edward Chow Journal: Support Care Cancer Date: 2018-05-28 Impact factor: 3.603